Pathogenesis of Parkinson's disease

Current Opinion in Investigational Drugs

Volumn 2, Issue 5, 2001, Pages 657-662

  Sherer, T B ^a   Betarbet, R ^a   Greenamyre, J T ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Synuclein; Dopaminergic; Excitotoxicity; Lewy body; Mitochondrial; MPP+; Oxidative stress; Parkin; Parkinson's disease; Rotenone; Ubiquitin

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; ALPHA SYNUCLEIN; PESTICIDE; ROTENONE; UBIQUITIN;

BIOCHEMISTRY; BRAIN DEGENERATION; CYTOPLASM; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC SYSTEM; ENVIRONMENTAL EXPOSURE; FAMILIAL DISEASE; GENE MUTATION; GENETIC DISORDER; HUMAN; HUMAN GENETICS; LEWY BODY; NEUROTOXICOLOGY; NIGRONEOSTRIATAL SYSTEM; OXIDATION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PROTEIN AGGREGATION; REVIEW;

ANIMALS; HUMANS; OXIDATIVE STRESS; PARKINSON DISEASE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0034991162     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Neurochemistry and neuropharmacology of Parkinson's disease
2. Mutation in α-synuclein in Lewy bodies
3. Point mutations (Thr240Arg and Ala311Stop) in the parkin gene
4. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
5. Homozygous deletions in parkin gene in European and North African families with autosomal recessive juvenile parkinsonism: The European consortium on genetic susceptibility in Parkinson's disease and the French Parkinson's disease genetics study group
6. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
7. The ubiquitin pathway in Parkinson's disease
8. Mutation in the α-synuclein gene identified in families with Parkinson's disease
9. 30Pro mutation in the gene encoding α-synuclein in Parkinson's disease
10. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain α-synuclein immunoreactivity
11. Ubiquitin carboxyl-terminal hydroxylase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases
12. Pathology and biology of the Lewy body
13. Binding of α-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation
14. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson's disease
15. A Drosophila model of Parkinson's disease
16. Dopaminergic loss and inclusion body formation in α-synuclein mice: Implications for neurodegenerative disorders
17. Environmental antecedents of young-onset Parkinson's disease
18. The risk of Parkinson's disease with exposure to pesticides, farming, well water and rural living
19. Parkinson's disease, pesticides, and gluathione transferase polymorphisms
20. Pesticides and Parkinson's disease
21. Parkinson's disease: A case-control study of occupational and environmental risk factors
22. Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss
23. Ecogenetics of Parkinson's disease: 4-Hydroxylation of debrisoquine
24. Chronic parkinsonism in humans due to a product of meridine-analog synthesis
25. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity
26. Inhibition of NADH-linked oxidation in brain oxidation in brain mitochondria by 1-mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydroyridine
27. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds
28. Mitochondrial function in Parkinson's disease
29. Electron transport chain abnormalities in idiopathic Parkinson's disease
30. Mitochondrial deficits in Parkinson's disease
31. Mitochondrial oxidative phosphorylation defects in Parkinson's disease
32. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease
33. Mitochondrial respiratory chain activity in skeletal muscle from patients with Parkinson's disease
34. Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy
35. Mitochondrial dysfunction in Parkinson's disease
36. Origin and functional consequences of the complex I defect in Parkinson's disease
37. Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease
38. Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson's disease family
39. Chronic systemic pesticide exposure reproduces features of Parkinson's disease
40. Alternative excitotoxic hypotheses
41. Bioenergetics and glutamate excitotoxicity
42. Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease
43. Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: Behavioural and immunohistochemical studies
44. Generation of superoxide anion by NADH hydrogenase of bovine mitochondria
45. +) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine submitochondrial particles
46. Interaction of α-phenyl-N-tert-butyl nitrone and alternative electron aceptors with complex I indicates a substrate reaction site upstream from the rotenone binding site
47. Oxidative mechanisms in nigral cell death in Parkinson's disease
48. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease
49. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson's disease
50. Alterations in glutathione levels in Parkinson's disease and neurodegenerative disorders affecting basal ganglia
51. Evidence for generation of oxidative stress in brain by MPTP: In vitro and in vivo studies in mice
52. Novel free radical spin traps protect against malonate and MPTP neurotoxicity
53. Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity
54. Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice
55. Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease
56. An in vitro model of Parkinson's disease: Chronic complex I inhibition
57. Enhanced vulnerability to oxidative stress by α-synuclein mutations and c-terminal truncation
58. Sensitization of neuronal cells to oxidative stress with mutated human α-synuclein
59. Dityrosine cross-linking promotes formation of stable α-synuclein polymers
60. Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions
61. In vivo autoxidation of dopamine in guinea pig striatium increases with age
62. The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it
63. Expression of α-synuclein, parkin, and ubiquitin carboxy-terminal hydroxylase L1 mRNA in human brain: Genes associated with familial Parkinson's disease
64. Immunocytochemical characterization of the mitochondrially encoded ND1 subunit of complex I (NADH:ubiquinone oxoreductase) in rat brain